论文部分内容阅读
作者测定了５７７例正常人和２４１例恶性肿瘤患者血清总唾液酸（ＴＳＡ）和血清脂质结合唾液酸（ＬＳＡ）的含量。结果表明：ＴＳＡ和ＬＳＡ的含量变化与疗效一致，治疗有效者ＴＳＡ和ＬＳＡ与正常人相比，均无显著性差异（Ｐ＞０．０５）；治疗无效（包括未经治疗）者与正常人相比除原发性肝癌、乳腺癌外均有显著性差异（Ｐ＜０．０１）。血清ＴＳＡ和ＬＳＡ测定对肺癌、胃癌、大肠癌等有临床诊断价值（Ｐ＜０．０１），对鼻咽癌诊断效果更好（Ｐ＜０．００１）。对肝癌、乳腺癌的诊断价值有限（Ｐ＞０．０５）。恶性肿瘤患者ＴＳＡ与ＬＳＡ含量间无相关关系（ｒ＝０．０９；Ｐ＞０．０５；ｎ＝１１７）。ＬＳＡ检测不能代替ＴＳＡ检测，两者应该联合检测以提高其阳性率。
The authors determined serum total sialic acid (TSA) and serum lipid-associated sialic acid (LSA) levels in 577 normal subjects and 241 patients with malignant tumors. The results showed that the content of TSA and LSA was consistent with the curative effect, and there was no significant difference between the TSA and LSA of the effective treatment group and the normal person (P>0.05). The patients with treatment ineffective (including untreated) and normal persons had no significant difference (P>0.05). Compared with primary liver cancer and breast cancer, there were significant differences (P<0.01). Serum TSA and LSA had clinical diagnostic value for lung cancer, gastric cancer, colorectal cancer, etc. (P<0.01), and a better diagnosis for nasopharyngeal carcinoma (P<0.001). The diagnostic value of liver cancer and breast cancer is limited (P>0.05). There was no correlation between TSA and LSA levels in patients with malignant tumors (r=0.09; P>0.05; n=117). The LSA test cannot replace the TSA test, both should be combined to increase the positive rate.